Cargando…
Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?
The immune checkpoint inhibitors have significantly modified the therapeutic landscape of advanced non-small cell lung cancer in second-line and, more recently, first-line settings. Because of the superior outcome with pembrolizumab as an upfront strategy, PD-L1 status should now be considered a new...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346853/ https://www.ncbi.nlm.nih.gov/pubmed/28285592 http://dx.doi.org/10.1186/s12916-017-0819-3 |